Date: 2012-10-15
Type of information: Company acquisition
Acquired company: Amdipharm (UK)
Acquiring company: Cinven (UK)
Amount: £ 367 million (€ 451.5 million)
Terms: Cinven has announced the acquisition of the Amdipharm Group, a family-owned international niche pharmaceuticals business, for a total consideration of £367 million. Amdipharm will operate initially as a standalone business but, over time, Cinven will look to merge Amdipharm with its existing portfolio company, Mercury Pharma, which it acquired in September 2012 (See http://biopharmanalyses.fr/merges-and-acquisitions/?pageid=125). The combination demonstrates the execution of Cinven's consolidation strategy within the niche pharmaceuticals sector.
Details: Mercury and Amdipharm each market mature, niche pharmaceuticals, both branded and unbranded. The businesses are highly complementary as Mercury's customer base is largely UK focused, whereas Amdipharm has a significantly greater international business, with its products sold in over 80 countries worldwide.
Amdipharm generates revenues of over £110 million. The founders will retain a significant minority stake in the combined business going forward.
Related: drug industry
pharmaceuticals
